BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-7. [PMID: 15772203 DOI: 10.1136/hrt.2004.042465] [Cited by in Crossref: 223] [Cited by in F6Publishing: 178] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Roldan T, Rios JJ, Villamañan E, Waxman AB. Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. Pulm Circ 2017;7:692-701. [PMID: 28677986 DOI: 10.1177/2045893217721903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Amin A. Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging 2013;8:75-84. [PMID: 23378750 DOI: 10.2147/CIA.S37818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 van Walraven C, Forster AJ. Anticoagulation control in the peri-hospitalization period. J Gen Intern Med 2007;22:727-35. [PMID: 17401605 DOI: 10.1007/s11606-006-0064-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gandara E, Wells PS. Will there be a role for genotyping in warfarin therapy?: . Current Opinion in Hematology 2010;17:439-43. [DOI: 10.1097/moh.0b013e32833c06b3] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
5 Vinereanu D, Napalkov D, Bergler-Klein J, Benczur B, Ciernik M, Gotcheva N, Medvedchikov A, Põder P, Simić D, Skride A, Tang W, Trusz-Gluza M, Vesely J. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study. J Thromb Thrombolysis 2021. [PMID: 33929686 DOI: 10.1007/s11239-021-02450-2] [Reference Citation Analysis]
6 Lane DA, Boos CJ, Lip GY. Anticoagulation Control With Vitamin K Antagonists. Chest 2006;129:1122-4. [DOI: 10.1378/chest.129.5.1122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Kim JH, Song YB, Shin DH, Kim JS, Choi JO, On YK, Kim JS. How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation? Yonsei Med J 2009;50:83-8. [PMID: 19259353 DOI: 10.3349/ymj.2009.50.1.83] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
8 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nieuwlaat R, Hubers L, Spyropoulos A, Eikelboom J, Connolly B, Van Spall H, Schulze K, Cuddy S, Stehouwer A, Schulman S, Connolly S. Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost 2017;108:1228-35. [DOI: 10.1160/th12-06-0433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
10 Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012;8:569-78. [DOI: 10.1038/nrneph.2012.160] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
11 Brouwer JL, Stoevelaar H, Sucker C. The clinical impact of different coagulometers on patient outcomes. Adv Ther 2014;31:639-56. [PMID: 24895179 DOI: 10.1007/s12325-014-0124-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Mcgrath ER, Eikelboom JW, Kapral MK, O'donnell MJ. Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. International Journal of Stroke 2014;9:71-8. [DOI: 10.1111/ijs.12158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2012;126:2309-16. [DOI: 10.1161/circulationaha.112.101808] [Cited by in Crossref: 114] [Cited by in F6Publishing: 35] [Article Influence: 11.4] [Reference Citation Analysis]
14 Lizán L. ["Be careful with indirect comparisons: the case of the new oral anticoagulants"]. Aten Primaria 2013;45:448-50. [PMID: 24206756 DOI: 10.1016/j.aprim.2013.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Hegener MA, Li H, Han D, Steckl AJ, Pauletti GM. Point-of-care coagulation monitoring: first clinical experience using a paper-based lateral flow diagnostic device. Biomed Microdevices 2017;19:64. [PMID: 28695382 DOI: 10.1007/s10544-017-0206-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
16 Lane DA, Lip GY. Maintaining therapeutic anticoagulation: the importance of keeping "within range". Chest 2007;131:1277-9. [PMID: 17494777 DOI: 10.1378/chest.07-0273] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2012;43:3442-53. [DOI: 10.1161/str.0b013e318266722a] [Cited by in Crossref: 181] [Cited by in F6Publishing: 65] [Article Influence: 18.1] [Reference Citation Analysis]
18 van Walraven C, Austin PC, Oake N, Wells P, Mamdani M, Forster AJ. The effect of hospitalization on oral anticoagulation control: A population-based study. Thrombosis Research 2007;119:705-14. [DOI: 10.1016/j.thromres.2006.05.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
19 Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, Croal B, Ramsay CR, Brazzelli M. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Health Technol Assess 2015;19:1-172. [PMID: 26138549 DOI: 10.3310/hta19480] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
20 Cawello W, Stockis A, Andreas JO, Dimova S. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci 2014;1329:18-32. [PMID: 25167889 DOI: 10.1111/nyas.12513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
21 Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for Primary Care: An Overview. Genes (Basel) 2020;11:E1337. [PMID: 33198260 DOI: 10.3390/genes11111337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS. Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med 2012;271:15-24. [PMID: 21995885 DOI: 10.1111/j.1365-2796.2011.02464.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
23 Guidoni CM, Obreli-neto PR, Pereira LRL. Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital. J Thromb Thrombolysis 2014;37:542-8. [DOI: 10.1007/s11239-013-1030-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 McIntyre WF, Conen D, Olshansky B, Halperin JL, Hayek E, Huisman MV, Lip GYH, Lu S, Healey JS. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program. Clin Cardiol 2018;41:744-51. [PMID: 29546729 DOI: 10.1002/clc.22936] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Alonso Roca R, Figueroa Guerrero CA, Mainar de Paz V, Arribas García MP, Sánchez Perruca L, Rodríguez Barrientos R, Casado López M, Pedraza Flechas AM. Grado de control del tratamiento anticoagulante oral en los centros de Atención Primaria de la Comunidad de Madrid: estudio CHRONOS-TAO. Medicina Clínica 2015;145:192-7. [DOI: 10.1016/j.medcli.2014.09.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
26 Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace 2018;20:253-62. [PMID: 28520924 DOI: 10.1093/europace/eux022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Cîmpan PL, Chira RI, Mocan M, Anton FP, Farcaş AD. Oral Anticoagulant Therapy-When Art Meets Science. J Clin Med 2019;8:E1747. [PMID: 31640208 DOI: 10.3390/jcm8101747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Steinberg BA. How I use anticoagulation in atrial fibrillation. Blood 2016;128:2891-8. [PMID: 27780804 DOI: 10.1182/blood-2016-07-693614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Barra S, Fynn S. Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. J Saudi Heart Assoc 2015;27:31-43. [PMID: 25544820 DOI: 10.1016/j.jsha.2014.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
30 Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee J, Shimizu A, Hayano M, Yano K. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. International Journal of Cardiology 2008;126:316-21. [DOI: 10.1016/j.ijcard.2007.06.020] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
31 Alshogran OY. Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Curr Drug Metab 2019;20:633-45. [PMID: 31267868 DOI: 10.2174/1389200220666190701095807] [Reference Citation Analysis]
32 Sherid M, Sifuentes H, Sulaiman S, Samo S, Husein H, Tupper R, Spurr C, Sridhar S. Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience. Korean J Gastroenterol 2015;65:205. [DOI: 10.4166/kjg.2015.65.4.205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Zeidler E, Goetz A, Zöllner C. Pharmakogenetik: Klinische Bedeutung in der Anästhesiologie. Anaesthesist 2013;62:874-86. [DOI: 10.1007/s00101-013-2233-3] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Yabeyu AB, Ayanaw MA, Haile KT, Kifle ZD. Evaluation of patients' knowledge of warfarin at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Metabol Open 2022;13:100155. [PMID: 34917918 DOI: 10.1016/j.metop.2021.100155] [Reference Citation Analysis]
35 Safouris A, Anagnostis P, Karlovasitou A, Karras S, Karagiannis A. Protecting the Brain and the Heart: Antithrombotic Treatment in Nonvalvular Atrial Fibrillation. Angiology 2014;65:372-8. [DOI: 10.1177/0003319713486014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis 2009;27:293-9. [PMID: 18392557 DOI: 10.1007/s11239-008-0219-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
37 Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics 2012;13:429-40. [DOI: 10.2217/pgs.11.184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
38 Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. Circulation 2009;120:1029-35. [DOI: 10.1161/circulationaha.109.856120] [Cited by in Crossref: 57] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
39 Semakula JR, Kisa G, Mouton JP, Cohen K, Blockman M, Pirmohamed M, Sekaggya-Wiltshire C, Waitt C. Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. Br J Clin Pharmacol 2021. [PMID: 33624331 DOI: 10.1111/bcp.14796] [Reference Citation Analysis]
40 Tong HY, Dávila-Fajardo CL, Borobia AM, Martínez-González LJ, Lubomirov R, Perea León LM, Blanco Bañares MJ, Díaz-Villamarín X, Fernández-Capitán C, Cabeza Barrera J, Carcas AJ; PGX-ACE Investigators Group. A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS One 2016;11:e0150456. [PMID: 26977927 DOI: 10.1371/journal.pone.0150456] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
41 Hess CN, Al-Khatib SM, Granger CB, Lopes R. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Rev Cardiovasc Ther 2013;11:1105-14. [PMID: 23992517 DOI: 10.1586/14779072.2013.824181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
42 Jalota A, Scarabelli TM, Saravolatz L, Bakhsh MU, Agrawal P, Jalota R, Chen-scarabelli C, Fuster V, Halperin J. Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther 2014;28:247-62. [DOI: 10.1007/s10557-014-6524-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Rovellini A, Folli C, Cardani F, Monzani V. Thromboembolic and haemorrhagic events in permanent atrial fibrillation: Observational study in an emergency department. European Journal of Internal Medicine 2009;20:756-9. [DOI: 10.1016/j.ejim.2009.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-641. [PMID: 20934556 DOI: 10.1016/j.ahj.2010.06.042] [Cited by in Crossref: 342] [Cited by in F6Publishing: 284] [Article Influence: 28.5] [Reference Citation Analysis]
45 Harel Z, Sholzberg M, Shah PS, Pavenski K, Harel S, Wald R, Bell CM, Perl J. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25:431-42. [PMID: 24385595 DOI: 10.1681/ASN.2013040361] [Cited by in Crossref: 76] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
46 Eljilany I, Elarref M, Shallik N, Elzouki AN, Bader L, El-Bardissy A, Abdelsamad O, Al-Badriyeh D, Cavallari LH, Elewa H. Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. Pharmgenomics Pers Med 2021;14:1069-80. [PMID: 34483679 DOI: 10.2147/PGPM.S322743] [Reference Citation Analysis]
47 Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola V, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, Mcmurray JJ, Oh B, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. Circulation 2013;127:2166-76. [DOI: 10.1161/circulationaha.112.142158] [Cited by in Crossref: 151] [Cited by in F6Publishing: 59] [Article Influence: 16.8] [Reference Citation Analysis]
48 Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:416-24. [PMID: 21712521 DOI: 10.1161/CIRCOUTCOMES.111.960591] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
49 John Camm A. Managing anticoagulation for atrial fibrillation: current issues and future strategies. J Intern Med 2013;273:31-41. [PMID: 23121422 DOI: 10.1111/joim.12001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J. Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 2013;168:2540-7. [PMID: 23664436 DOI: 10.1016/j.ijcard.2013.03.059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
51 You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-75S. [PMID: 22315271 DOI: 10.1378/chest.11-2304] [Cited by in Crossref: 603] [Cited by in F6Publishing: 521] [Article Influence: 60.3] [Reference Citation Analysis]
52 Jiménez-Varo E, Cañadas-Garre M, Henriques CI, Pinheiro AM, Gutiérrez-Pimentel MJ, Calleja-Hernández MÁ. Pharmacogenetics role in the safety of acenocoumarol therapy. Thromb Haemost 2014;112:522-36. [PMID: 24919870 DOI: 10.1160/TH13-11-0941] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
53 Carmo J, Ferreira J, Costa F, Carmo P, Cavaco D, Carvalho S, Morgado F, Adragão P, Mendes M. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials. International Journal of Cardiology 2017;244:196-201. [DOI: 10.1016/j.ijcard.2017.06.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
54 Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. Journal of Electrocardiology 2013;46:45-50. [DOI: 10.1016/j.jelectrocard.2012.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
55 Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost 2015;114:70-7. [PMID: 25948532 DOI: 10.1160/TH14-09-0754] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mearns ES, Hawthorne J, Song JS, Coleman CI. Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open 2014;4:e005379. [PMID: 24951111 DOI: 10.1136/bmjopen-2014-005379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Fuller R, Dudley NJ. Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes? Heart 2005;91:423-4. [PMID: 15772185 DOI: 10.1136/hrt.2004.047902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. [DOI: 10.1161/circoutcomes.108.796185] [Cited by in Crossref: 357] [Cited by in F6Publishing: 99] [Article Influence: 25.5] [Reference Citation Analysis]
59 Puttasung N, Davey AK, Badrick T, Anoopkumar-Dukie S, Bernaitis N. Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control. J Stroke Cerebrovasc Dis 2021;30:105620. [PMID: 33493875 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105620] [Reference Citation Analysis]
60 Marinigh R, Lip GY, Lane DA. Stroke prevention in atrial fibrillation patients. Expert Opinion on Pharmacotherapy 2010;11:2331-50. [DOI: 10.1517/14656566.2010.498819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
61 Macedo AF, Bell J, Mccarron C, Conroy R, Richardson J, Scowcroft A, Sunderland T, Rotheram N. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. Thrombosis Research 2015;136:250-60. [DOI: 10.1016/j.thromres.2015.06.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
62 Gallagher A, Setakis E, Plumb J, Clemens A, van Staa T. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2017;106:968-77. [DOI: 10.1160/th11-05-0353] [Cited by in Crossref: 256] [Cited by in F6Publishing: 61] [Article Influence: 51.2] [Reference Citation Analysis]
63 Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, Sherrill B. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2. SAGE Open Med 2015;3:2050312115613350. [PMID: 27092254 DOI: 10.1177/2050312115613350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
64 Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. The Lancet 2010;376:975-83. [DOI: 10.1016/s0140-6736(10)61194-4] [Cited by in Crossref: 720] [Cited by in F6Publishing: 163] [Article Influence: 60.0] [Reference Citation Analysis]
65 Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008;39:7-9. [PMID: 18048849 DOI: 10.1161/STROKEAHA.107.496554] [Cited by in Crossref: 34] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
66 Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015;132:1252-60. [PMID: 26199338 DOI: 10.1161/CIRCULATIONAHA.115.015710] [Cited by in Crossref: 123] [Cited by in F6Publishing: 57] [Article Influence: 17.6] [Reference Citation Analysis]
67 Duan L, Zhang N, Yan H, Guo Y, Hong C, Yang X, Su X, Chen R, Zhou Y, Zhong N, Liu C. Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism. Clinica Chimica Acta 2016;459:25-9. [DOI: 10.1016/j.cca.2016.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Hoffman R, Brenner B. The promise of novel direct oral anticoagulants. Best Pract Res Clin Haematol 2012;25:351-60. [PMID: 22959551 DOI: 10.1016/j.beha.2012.06.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
69 Kim BJ, Kim HJ, Do Y, Lee JH, Park KY, Cha JK, Kim HY, Kwon JH, Lee KB, Kim DE, Ha SW, Sohn SI, Kwon SU. The impact of prior antithrombotic status on cerebral infarction in patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2014;23:2054-9. [PMID: 25113085 DOI: 10.1016/j.jstrokecerebrovasdis.2014.03.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
70 Navarro JL, Cesar JM, Fernández MA, Fontcuberta J, Reverter JC, Gol-freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Revista Española de Cardiología 2007;60:1226-32. [DOI: 10.1157/13113927] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
71 Bergman M, Dicker D, Blumberger N, Brener ZZ, Ori Y, Salman H. Prolonged international normalized ratio during the first year of warfarin treatment. Am J Med Sci 2014;348:71-4. [PMID: 24949726 DOI: 10.1097/MAJ.0000000000000209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;:CD009893. [PMID: 24677203 DOI: 10.1002/14651858.CD009893.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
73 Roldan T, Landzberg MJ, Deicicchi DJ, Atay JK, Waxman AB. Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. J Heart Lung Transplant 2016;35:151-64. [PMID: 26527532 DOI: 10.1016/j.healun.2015.10.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
74 Wrigley BJ, Lip GY, Shantsila E. Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. Int J Clin Pract 2010;64:835-8. [PMID: 20584215 DOI: 10.1111/j.1742-1241.2010.02351.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
75 Hong KS, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, Cha JK, Yoon BW, Rha JH, Lee BC, Park JM, Park MS, Lee J, Choi JC, Kim DE, Lee KB, Park TH, Lee JS, Kim SE, Lee J. Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. J Clin Neurol 2017;13:273-80. [PMID: 28748679 DOI: 10.3988/jcn.2017.13.3.273] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
76 Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) clinical quality study group. Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS One 2015;10:e0144314. [PMID: 26636337 DOI: 10.1371/journal.pone.0144314] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
77 Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju C, Schein JR. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. Blood Coagulation & Fibrinolysis 2016;27:899-906. [DOI: 10.1097/mbc.0000000000000515] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Bae HJ, Heo JH, Jung KH, Lee YS, Hong KS, Seo WK, Koo J, Cha JK, Lee MJ, Seo BJ, Kim YJ, Kang S, Seok J, Lee J, Chung CS. Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. PLoS One 2018;13:e0202803. [PMID: 30388109 DOI: 10.1371/journal.pone.0202803] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, Lensing AW. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015;135:281-8. [PMID: 25483215 DOI: 10.1016/j.thromres.2014.11.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
80 Boos CJ, Lip GY. Ximelagatran: An eulogy. Thrombosis Research 2006;118:301-4. [DOI: 10.1016/j.thromres.2006.02.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
81 Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH, Barallon R, de Boer A, Daly A, Maitland-van der Zee A, Redekop K, Stingl J, Manolopoulos VG, Rosendaal FR, Wadelius M. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Thrombosis Research 2015;136:94-100. [DOI: 10.1016/j.thromres.2015.04.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
82 Hutchinson-Jones NW, Didcott SK, Jones MD, Crowe JN. Implementation of a standardised annual anticoagulation specialist review in primary care. Prim Health Care Res Dev 2020;21:e17. [PMID: 32513329 DOI: 10.1017/S1463423620000171] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Schiele F, van Ryn J, Litzenburger T, Ritter M, Seeliger D, Nar H. Structure-guided residence time optimization of a dabigatran reversal agent. MAbs 2015;7:871-80. [PMID: 26047352 DOI: 10.1080/19420862.2015.1057364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
84 Roller RE, Iglseder B, Dovjak P, Lechleitner M, Sommeregger U, Benvenuti-falger U, Otto R, Böhmdorfer B, Gosch M. Blutungskomplikationen bei geriatrischen Patienten unter oraler Antikoagulation – Aspekte der Polypragmasie. Wien Med Wochenschr 2010;160:270-5. [DOI: 10.1007/s10354-010-0785-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
85 Zheng Y, Sorensen SV, Gonschior A, Noack H, Heinrich-nols J, Sunderland T, Kansal AR. Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting. Clinical Therapeutics 2014;36:2015-2028.e2. [DOI: 10.1016/j.clinthera.2014.09.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
86 Tedders KM, Lucey MF, Edwin SB. Evaluation of pharmacist-managed dabigatran in an inpatient setting. Ann Pharmacother 2013;47:1649-53. [PMID: 24259619 DOI: 10.1177/1060028013508643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
87 Nieuwlaat R, Barker L, Kim YK, Haynes RB, Eikelboom JW, Yusuf S, Connolly SJ. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res 2010;125:e128-31. [PMID: 19932501 DOI: 10.1016/j.thromres.2009.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
88 Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther 2011;33:1371-80. [PMID: 21981797 DOI: 10.1016/j.clinthera.2011.09.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
89 Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111. [PMID: 16983400 DOI: 10.1038/sj.tpj.6500417] [Cited by in Crossref: 225] [Cited by in F6Publishing: 182] [Article Influence: 14.1] [Reference Citation Analysis]
90 Harris DE, Thayer D, Wang T, Brooks C, Murley G, Gravenor M, Hill NR, Lister S, Halcox J. An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). Eur Heart J Cardiovasc Pharmacother 2021;7:40-9. [PMID: 31774502 DOI: 10.1093/ehjcvp/pvz071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
91 Palareti G, Antonucci E, Lip G, Testa S, Guazzaloca G, Falanga A, Pengo V, Poli D; for the START-Register Participants. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE: A real-life inception cohort study. Thromb Haemost 2017;115:1101-8. [DOI: 10.1160/th15-10-0830] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
92 Janzic A, Kos M. Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control. PharmacoEconomics 2015;33:395-408. [DOI: 10.1007/s40273-014-0246-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
93 Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal. Pharmacoeconomics 2013;31:551-62. [PMID: 23620211 DOI: 10.1007/s40273-013-0051-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
94 Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation 2008;118:2029-37. [DOI: 10.1161/circulationaha.107.750000] [Cited by in Crossref: 610] [Cited by in F6Publishing: 198] [Article Influence: 43.6] [Reference Citation Analysis]
95 Mohammed S, Aljundi AH, Kasem M, Alhashemi M, El-Menyar A. Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. J Adv Pharm Technol Res 2017;8:14-8. [PMID: 28217549 DOI: 10.4103/2231-4040.197370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
96 Testa L, Andreotti F, Biondi Zoccai G, Burzotta F, Bellocci F, Crea F. Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients. International Journal of Cardiology 2007;122:117-24. [DOI: 10.1016/j.ijcard.2006.11.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
97 Strunets A, Mirza M, Sra J, Jahangir A. Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly. Expert Review of Clinical Pharmacology 2014;6:677-89. [DOI: 10.1586/17512433.2013.842125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
98 Currie CJ, Jones M, Goodfellow J, McEwan P, Morgan CL, Emmas C, Peters JR. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006;92:196-200. [PMID: 15883133 DOI: 10.1136/hrt.2004.058339] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
99 Nieuwlaat R, Connolly SJ, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB; CCDSS Systematic Review Team. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review. Implement Sci 2011;6:90. [PMID: 21824384 DOI: 10.1186/1748-5908-6-90] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
100 Karthikeyan G, Zühlke L, Engel M, Rangarajan S, Yusuf S, Teo K, Mayosi BM. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. Am Heart J 2012;163:535-40.e1. [PMID: 22520517 DOI: 10.1016/j.ahj.2012.01.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
101 Hynicka LM, Cahoon WD, Bukaveckas BL. Genetic Testing for Warfarin Therapy Initiation. Ann Pharmacother 2008;42:1298-303. [DOI: 10.1345/aph.1l127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
102 Madhavan M, Hu TY, Gersh BJ, Roger VL, Killian J, Weston SA, Graff-Radford J, Asirvatham SJ, Chamberlain AM. Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. Mayo Clin Proc 2018;93:145-54. [PMID: 29329798 DOI: 10.1016/j.mayocp.2017.09.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
103 Belley-cote E, Hanif H, D’aragon F, Eikelboom J, Anderson J, Borgman M, Jonas D, Kimmel S, Manolopoulos V, Baranova E, Maitland-van der Zee A, Pirmohamed M, Whitlock R. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation: A systematic review and meta-analysis. Thromb Haemost 2017;114:768-77. [DOI: 10.1160/th15-01-0071] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
104 Mearns ES, White CM, Kohn CG, Hawthorne J, Song JS, Meng J, Schein JR, Raut MK, Coleman CI. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 2014;12:14. [PMID: 25024644 DOI: 10.1186/1477-9560-12-14] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 8.9] [Reference Citation Analysis]
105 Xu XS, Moore K, Burton P, Stuyckens K, Mueck W, Rossenu S, Plotnikov A, Gibson M, Vermeulen A. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br J Clin Pharmacol 2012;74:86-97. [PMID: 22242932 DOI: 10.1111/j.1365-2125.2012.04181.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
106 Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010;10:21. [PMID: 20487528 DOI: 10.1186/1471-2261-10-21] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
107 Wright DFB, Duffull SB. A Bayesian Dose-Individualization Method for Warfarin. Clin Pharmacokinet 2013;52:59-68. [DOI: 10.1007/s40262-012-0017-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
108 Slostad B, Lee K, Trybula M, Konda S, Macrinici V, Frazin L, Kansal M. A quantitative gain-independent assessment of the left atrial appendage as a method of thromboembolic risk stratification. J Clin Ultrasound 2021. [PMID: 34967953 DOI: 10.1002/jcu.23123] [Reference Citation Analysis]
109 Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016;353:i2868. [PMID: 27306620 DOI: 10.1136/bmj.i2868] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 12.2] [Reference Citation Analysis]
110 Navgren M, Forsblad J, Wieloch M. Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. J Thromb Thrombolysis 2014;38:98-104. [DOI: 10.1007/s11239-013-1011-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
111 Tay KH, Lane DA, Lip GY. Challenges facing anticoagulation among the elderly and frail. Age Ageing 2009;38:140-2. [PMID: 19155538 DOI: 10.1093/ageing/afn295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
112 Morgan CL, Mcewan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thrombosis Research 2009;124:37-41. [DOI: 10.1016/j.thromres.2008.09.016] [Cited by in Crossref: 204] [Cited by in F6Publishing: 158] [Article Influence: 15.7] [Reference Citation Analysis]
113 Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, Drost P. The Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost 2013;19:619-31. [DOI: 10.1177/1076029613486539] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
114 Ruigómez A, García Rodríguez LA, Johansson S, Wallander MA, Edvardsson N. Risk of cerebrovascular accident after a first diagnosis of atrial fibrillation. Clin Cardiol 2007;30:624-8. [PMID: 18069679 DOI: 10.1002/clc.20178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
115 Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006;62:509-11. [PMID: 17061959 DOI: 10.1111/j.1365-2125.2006.02806.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 137] [Article Influence: 12.6] [Reference Citation Analysis]
116 Kocael A, Eronat AP, Tüzüner MB, Ekmekçi A, Orhan AL, İkizceli İ, Yılmaz-Aydoğan H, Öztürk O. Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. Mol Biol Rep 2019;46:1825-33. [PMID: 30712247 DOI: 10.1007/s11033-019-04634-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
117 Verhoef TI, Redekop WK, Langenskiold S, Kamali F, Wadelius M, Burnside G, Maitland-van der Zee A, Hughes DA, Pirmohamed M. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics J 2016;16:478-84. [DOI: 10.1038/tpj.2016.41] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
118 Hammill BG, Curtis LH, Qualls LG, Hastings SN, Wang V, Maciejewski ML. Linkage of Laboratory Results to Medicare Fee-for-Service Claims. Med Care 2015;53:974-9. [PMID: 26390069 DOI: 10.1097/MLR.0000000000000420] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
119 DeCarolis DD, Chen YC, Westanmo AD, Conley C, Gravely AA, Khan FB. Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. Am J Health Syst Pharm 2019;76:1273-80. [PMID: 31418789 DOI: 10.1093/ajhp/zxz127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
121 Hasan SS, Kow CS, Curley LE, Baines DL, Babar ZU. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Expert Rev Pharmacoecon Outcomes Res 2018;18:371-7. [PMID: 29741099 DOI: 10.1080/14737167.2018.1474101] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 AlAmmari M, Sultana K, AlHarbi SN, Marenga AS, AlTuraiki A, Althemery AU, Alfaifi AA, AlShehri A, Aqeel BF. Validation and Psychometric Properties of the Arabic Version of the Duke Anticoagulation Satisfaction Scale (DASS). Front Pharmacol 2020;11:587489. [PMID: 33390960 DOI: 10.3389/fphar.2020.587489] [Reference Citation Analysis]
123 Marrast L, Evans M, Ozonoff A, Henault LE, Rose AJ. Using highly variable warfarin dosing to identify patients at risk for adverse events. Thromb J 2011;9:14. [PMID: 21985504 DOI: 10.1186/1477-9560-9-14] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Edwards F, Arkell P, Fong AYY, Roberts LM, Gendy D, Wong CS, Ngu JCY, Tiong LL, Bibi FMS, Lai LYH, Ong TK, Abouyannis M. Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. J Thromb Thrombolysis 2014;38:226-34. [DOI: 10.1007/s11239-013-1017-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
125 Norgard NB, Dinicolantonio JJ, Topping TJ, Wee B. Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis 2012;3:123-36. [PMID: 23251773 DOI: 10.1177/2040622312438934] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
126 Leitner JM, Mannhalter C, Jilma B. Genetic variations and their influence on risk and treatment of venous thrombosis. Pharmacogenomics 2008;9:423-37. [PMID: 18384256 DOI: 10.2217/14622416.9.4.423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Erküner Ö, Claessen R, Pisters R, Schulmer G, Ramaekers R, Sonneveld L, Dudink E, Lankveld T, Limantoro I, Weijs B, Pison L, Blaauw Y, de Vos CB, Crijns HJ. Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events. Int J Cardiol 2016;225:337-41. [PMID: 27756038 DOI: 10.1016/j.ijcard.2016.10.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Costa GLDB, Lamego RM, Colosimo EA, Valacio RA, Moreira MDCV. Identifying Potential Predictors of High-Quality Oral Anticoagulation Assessed by Time in Therapeutic International Normalized Ratio Range: A Prospective, Long-Term, Single-Center, Observational Study. Clinical Therapeutics 2012;34:1511-20. [DOI: 10.1016/j.clinthera.2012.06.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
129 Yazdan-Ashoori P, Oqab Z, McIntyre WF, Quinn KL, Oosten EV, Hopman WM, Baranchuk A. How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation? Prim Health Care Res Dev 2017;18:472-81. [PMID: 28464979 DOI: 10.1017/S1463423617000196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
130 Golwala H, Dib C, Abu-fadel MS, Tafur A. A New Era of Antithrombotic Therapy in Patients With Atrial Fibrillation. The American Journal of the Medical Sciences 2012;344:128-35. [DOI: 10.1097/maj.0b013e3182429b1e] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
131 Chang JY, Jung S, Park H, Han MK. Major vessel occlusion may predict subtherapeutic anticoagulation intensity and feasibility of administration of intravenous thrombolytics. PLoS One 2017;12:e0170978. [PMID: 28158211 DOI: 10.1371/journal.pone.0170978] [Reference Citation Analysis]
132 Wright DF, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res 2011;28:1100-11. [PMID: 21301936 DOI: 10.1007/s11095-011-0369-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
133 Salmasi S, De Vera MA, Barry A, Bansback N, Harrison M, Lynd LD, Loewen PS. Assessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysis. Ann Pharmacother 2019;53:773-85. [DOI: 10.1177/1060028019835845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
134 Phelps E, Delate T, Witt DM, Shaw PB, McCool KH, Clark NP. Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Thromb Res 2018;163:54-9. [PMID: 29407629 DOI: 10.1016/j.thromres.2018.01.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
135 Madhavan M, Holmes DN, Piccini JP, Freeman JV, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Pieper K, Peterson ED, Chan PS, Allen LA, Singer DE, Naccarelli GV, Reiffel JA, Steinberg BA, Gersh BJ; ORBIT AF Investigators. Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). Am J Cardiol 2020;132:66-71. [PMID: 32826041 DOI: 10.1016/j.amjcard.2020.07.006] [Reference Citation Analysis]
136 Belley-Côté EP, Whitlock RP, French B, Evaniew N, Kimmel SE. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials: Comment. Thromb Res 2015;136:180-1. [PMID: 26004747 DOI: 10.1016/j.thromres.2015.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
137 Brekelmans M, Middeldorp S, Coppens M. Direct factor Xa inhibitor edoxaban: from bench to clinical practice. Expert Review of Hematology 2015;8:707-25. [DOI: 10.1586/17474086.2015.1111756] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Perrotta PL, Svensson AM. Molecular diagnostics in hemostatic disorders. Clin Lab Med 2009;29:367-90. [PMID: 19665683 DOI: 10.1016/j.cll.2009.04.001] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
139 Dissmann R, Cromme LJ, Salzwedel A, Taborski U, Kunath J, Gäbler F, Heyne K, Völler H. [Computer aided dosage management of phenprocoumon anticoagulation therapy. Clinical validation]. Hamostaseologie 2014;34:226-32. [PMID: 24888786 DOI: 10.5482/HAMO-13-06-0030] [Reference Citation Analysis]
140 Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM. Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs 2008;17:925-37. [PMID: 18491993 DOI: 10.1517/13543784.17.6.925] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
141 Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, Yılmaz MB, Zoghi M; WARFARIN-TR Study Collaborates. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600. [PMID: 27004711 DOI: 10.5152/AnatolJCardiol.2015.6474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
142 Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 2006;61:746-51. [PMID: 16722840 DOI: 10.1111/j.1365-2125.2006.02679.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
143 Semakula JR, Mouton JP, Jorgensen A, Hutchinson C, Allie S, Semakula L, French N, Lamorde M, Toh CH, Blockman M, Sekaggya-Wiltshire C, Waitt C, Pirmohamed M, Cohen K. A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS One 2020;15:e0227458. [PMID: 31995565 DOI: 10.1371/journal.pone.0227458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
144 Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol 2010;663:181-201. [PMID: 20617418 DOI: 10.1007/978-1-60761-803-4_6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
145 Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics 2012;13:1405-17. [PMID: 22966889 DOI: 10.2217/pgs.12.124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
146 Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2021:pvab018. [PMID: 33638977 DOI: 10.1093/ehjcvp/pvab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Belley-côté EP, Whitlock RP, French B, Evaniew N, Kimmel SE. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis: comment. J Thromb Haemost 2015;13:1162-4. [DOI: 10.1111/jth.12903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf 2009;35:146-55. [PMID: 19326806 DOI: 10.1016/s1553-7250(09)35019-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
149 Anthony CJ, Karim S, Ackroyd-stolarz S, Fry A, Murphy NG, Christie R, Zed PJ. Intensity of Anticoagulation with Warfarin and Risk of Adverse Events in Patients Presenting to the Emergency Department. Ann Pharmacother 2011;45:881-7. [DOI: 10.1345/aph.1p670] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
150 Roldan T, Villamañán E, Rios JJ, Waxman AB. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. Thrombosis Research 2017;160:83-90. [DOI: 10.1016/j.thromres.2017.10.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
151 Pirmohamed M, Kamali F, Daly AK, Wadelius M. Oral anticoagulation: a critique of recent advances and controversies. Trends Pharmacol Sci 2015;36:153-63. [PMID: 25698605 DOI: 10.1016/j.tips.2015.01.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
152 Mansur Ade P, Takada JY, Avakian SD, Strunz CM. Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation. Clinics (Sao Paulo) 2012;67:543-6. [PMID: 22760890 DOI: 10.6061/clinics/2012(06)01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
153 Wilson AS, Vazquez SR, Saunders JA, Witt DM. Concordance of experienced-based maintenance warfarin dosing vs. algorithm-based dosing. Thrombosis Update 2022;6:100093. [DOI: 10.1016/j.tru.2021.100093] [Reference Citation Analysis]
154 Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014;103:173-82. [PMID: 23999974 DOI: 10.1007/s00392-013-0616-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
155 Witt DM. Quality measures and benchmarking for warfarin therapy. J Thromb Thrombolysis 2011;31:242-8. [DOI: 10.1007/s11239-011-0570-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
156 Lowe BS, Kusunose K, Motoki H, Varr B, Shrestha K, Whitman C, Tang WHW, Thomas JD, Klein AL. Prognostic Significance of Left Atrial Appendage “Sludge” in Patients with Atrial Fibrillation: A New Transesophageal Echocardiographic Thromboembolic Risk Factor. Journal of the American Society of Echocardiography 2014;27:1176-83. [DOI: 10.1016/j.echo.2014.08.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
157 Razouki Z, Ozonoff A, Zhao S, Jasuja GK, Rose AJ. Improving Quality Measurement for Anticoagulation: Adding International Normalized Ratio Variability to Percent Time in Therapeutic Range. Circ Cardiovasc Qual Outcomes 2014;7:664-9. [DOI: 10.1161/circoutcomes.114.000804] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
158 Leithäuser B, Kasch F, Broemel T, Park JW. [Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation]. Herz 2010;35:576-80. [PMID: 20927501 DOI: 10.1007/s00059-010-3384-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
159 Ruff CT, Braunwald E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther 2010;15:210-9. [PMID: 20484119 DOI: 10.1177/1074248410366448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
160 Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis 2008;26:167-74. [PMID: 18807225 DOI: 10.1007/s11239-008-0272-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
161 van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee A; for the EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European Heart Journal 2011;32:1909-17. [DOI: 10.1093/eurheartj/ehr116] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 6.9] [Reference Citation Analysis]
162 Issa AM. Clinical applications of pharmacogenomics to adverse drug reactions. Expert Review of Clinical Pharmacology 2014;1:251-60. [DOI: 10.1586/17512433.1.2.251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
163 Choudhury A, Lip GY. How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis. Heart 2005;91:425-6. [PMID: 15772186 DOI: 10.1136/hrt.2004.052480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
164 Dahl OE, Huisman MV. Dabigatran etexilate: advances in anticoagulation therapy. Expert Review of Cardiovascular Therapy 2014;8:771-4. [DOI: 10.1586/erc.10.67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
165 Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, Connolly SJ; ACTIVE Investigators. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res 2012;129:715-9. [PMID: 21924760 DOI: 10.1016/j.thromres.2011.08.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
166 Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, Wang TJ, Januzzi JL. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients With Chronic Heart Failure. JACC: Heart Failure 2014;2:65-72. [DOI: 10.1016/j.jchf.2013.10.005] [Cited by in Crossref: 114] [Cited by in F6Publishing: 100] [Article Influence: 14.3] [Reference Citation Analysis]
167 Aspinall SL, Zhao X, Handler SM, Stone RA, Kosmoski JC, Libby EA, Francis SD, Goodman DA, Roman RD, Bieber HL, Voisine JM, Jeffery SM, Hepfinger CA, Hagen DG, Martin MM, Hanlon JT. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc 2010;58:1475-80. [PMID: 20662956 DOI: 10.1111/j.1532-5415.2010.02967.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
168 Kansal AR, Sharma M, Bradley-kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: Comparative efficacy and cost-effectiveness. Thromb Haemost 2017;108:672-82. [DOI: 10.1160/th12-06-0388] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
169 Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-58. [PMID: 23036896 DOI: 10.1016/S0140-6736(12)60986-6] [Cited by in Crossref: 130] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
170 Paradise HT, Berlowitz DR, Ozonoff A, Miller DR, Hylek EM, Ash AS, Jasuja GK, Zhao S, Reisman JI, Rose AJ. Outcomes of anticoagulation therapy in patients with mental health conditions. J Gen Intern Med 2014;29:855-61. [PMID: 24549520 DOI: 10.1007/s11606-014-2784-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
171 Rikala M, Kastarinen H, Tiittanen P, Huupponen R, Korhonen MJ. Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland. Clin Epidemiol 2016;8:23-35. [PMID: 26917975 DOI: 10.2147/CLEP.S91379] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
172 Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 2010;12:283-91. [PMID: 20228265 DOI: 10.2353/jmoldx.2010.090110] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
173 Costa GLDB, Ferreira DC, Valacio RA, Vieira Moreira MDC. Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. Age and Ageing 2011;40:375-81. [DOI: 10.1093/ageing/afr020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
174 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, Lip GYH, Weitz J, Fauchier L, Lane D, Boriani G, Goette A, Keegan R, Macfadyen R, Chiang C, Joung B, Shimizu W; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace 2018;20:1231-42. [DOI: 10.1093/europace/euy054] [Cited by in Crossref: 122] [Cited by in F6Publishing: 103] [Article Influence: 30.5] [Reference Citation Analysis]
175 Tzeis S, Andrikopoulos G. Novel anticoagulants for atrial fibrillation: a critical appraisal. Angiology. 2012;63:164-170. [PMID: 22007032 DOI: 10.1177/0003319711422808] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
176 van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of Study Setting on Anticoagulation Control. Chest 2006;129:1155-66. [DOI: 10.1378/chest.129.5.1155] [Cited by in Crossref: 345] [Cited by in F6Publishing: 286] [Article Influence: 21.6] [Reference Citation Analysis]
177 Garrison SR, Green L, Kolber MR, Korownyk CS, Olivier NM, Heran BS, Flesher ME, Allan GM. The Effect of Warfarin Administration Time on Anticoagulation Stability (INRange): A Pragmatic Randomized Controlled Trial. Ann Fam Med 2020;18:42-9. [PMID: 31937532 DOI: 10.1370/afm.2488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Adlan A, Lip GYH. Preventative Measures of Stroke in Patients With Atrial Fibrillation. J Atr Fibrillation 2012;4:399. [PMID: 28496725 DOI: 10.4022/jafib.399] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
179 Kakar P, Lip GY. Atrial fibrillation and stroke prevention. Expert Review of Neurotherapeutics 2014;6:1523-30. [DOI: 10.1586/14737175.6.10.1523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
180 Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P, Bloch A. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace 2010;12:482-7. [PMID: 20179174 DOI: 10.1093/europace/euq006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
181 Shin D, Yoon D, Lim SG, Hong JM, Park RW, Lee JS. Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study. PLoS One 2016;11:e0158130. [PMID: 27386858 DOI: 10.1371/journal.pone.0158130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
182 Van Den Ham HA, Klungel OH, Leufkens HGM, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: Patterns of anticoagulation control in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis 2013;11:107-15. [DOI: 10.1111/jth.12041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
183 Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: treatment. Nat Rev Cardiol 2017;14:113-24. [PMID: 27786235 DOI: 10.1038/nrcardio.2016.171] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
184 Ezekowitz MD, Nagarakanti R. Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol 2011;32:173-80. [PMID: 21717198 DOI: 10.1007/s10840-011-9593-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Groenendaal D, Strabach G, Garcia-Hernandez A, Kadokura T, Heeringa M, Mol R, Eltink C, Onkels H. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol 2013;75:440-9. [PMID: 22642721 DOI: 10.1111/j.1365-2125.2012.04346.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
186 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [PMID: 29562325 DOI: 10.1093/eurheartj/ehy136] [Cited by in Crossref: 935] [Cited by in F6Publishing: 657] [Article Influence: 311.7] [Reference Citation Analysis]
187 Sheibani R, Sheibani M, Hejazi Y, Eslami S. Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial. Electron Physician 2017;9:4732-6. [PMID: 28894528 DOI: 10.19082/4732] [Reference Citation Analysis]
188 Van Es J, Eerenberg ES, Kamphuisen PW, Büller HR. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011;9 Suppl 1:265-74. [PMID: 21781263 DOI: 10.1111/j.1538-7836.2011.04334.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
189 Harris K, Mant J. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. Int J Clin Pract 2013;67:647-55. [PMID: 23621153 DOI: 10.1111/ijcp.12177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
190 Huber K, Connolly SJ, Kher A, Christory F, Dan GA, Hatala R, Kiss RG, Meier B, Merkely B, Pieske B, Potpara T, Stępińska J, Klun NV, Vinereanu D, Widimský P. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. Int J Clin Pract 2013;67:516-26. [PMID: 23557519 DOI: 10.1111/ijcp.12147] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
191 Nutescu EA, Bathija S, Sharp LK, Gerber BS, Schumock GT, Fitzgibbon ML. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. Pharmacotherapy 2011;31:1161-74. [PMID: 22122179 DOI: 10.1592/phco.31.12.1161] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]